FeesSafety
Pluang+

EU approves extended dosing and faster infusion options for cancer drug Libtayo

Market News
17 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
EU approves extended dosing and faster infusion options for cancer drug Libtayo

The European Commission has approved a new flexible dosing schedule for Regeneron's cancer drug Libtayo (cemiplimab), allowing a higher 700 mg dose every six weeks after an initial 12-week period of 350 mg every three weeks. Additionally, patients who tolerate the first 30-minute infusion of 350 mg can have subsequent infusions shortened to 15 minutes. This approval covers all six approved cancer indications in the EU, including skin, lung, and cervical cancers, aiming to reduce treatment burden and improve patient convenience. A similar dosing regimen is under review in the U.S. with a decision expected in March 2027.

Regeneron Pharmaceuticals Inc (REGN) shares trade at USD 949.00 on Pluang as of Nov 17, 2026 19:12 WIB. The stock shows a slight 0.36% decline today with a market cap of $98.52 billion. Investor activity on Pluang is balanced but leans slightly toward selling, with 55% sell orders and 45% buy orders.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App